BioPharma Credit PLC USD · LSE:BPCP

BioPharma Credit PLC USD — BioPharma Credit — Debt Investor Presentation (September 2023)

30 slides from BioPharma Credit PLC USD's debt investor presentation, Sep 1, 2023

  1. Slide 1: Debt Capital for the Life Sciences Industry

    Debt Capital for the Life Sciences Industry COMPANY PRESENTATION – September 1, 2023 For additional information please email: ir@bpcruk.com or visit BioPharma Credit’s website at www.bpcruk.com

  2. Slide 2: Disclaimer

    Disclaimer This presentation of information relating to BioPharma Credit PLC (“BPCR”) is confidential and is intended solely for the information and exclusive use of the person to whom it has been provided. It is not to be reproduced, or transmitted, in whole or in part, to third parties. This prese

  3. Slide 3: Experienced Investment Team

    Experienced Investment Team Pharmakon Advisors, LP Pedro Gonzalez de Cosio Martin Friedman Pablo Legorreta Co-Founder, Principal and CEO Principal Co-Founder and Principal „ Co-founded Pharmakon in 2009 „ Joined Pharmakon in 2011 „Co-Founded Pharmakon in 2009 after 17 years in structured after 18 ye

  4. Slide 4: Investment Opportunity – Summary

    Investment Opportunity – Summary Investments in Approved Life Sciences Products – No Clinical Trial or Approval Risk „ Debt investments backed by life sciences products (drugs, devices and diagnostics) „ Collateral value assigned only to approved products in their approved indications and territorie

  5. Slide 5: BPCR has generated consistent returns since IPO

    BPCR has generated consistent returns since IPO1 BPCR annualized2 dividends per share in US$ $0.140 Interim Special $0.120 $0.100 „ Interim dividend has consistently met the annualized $0.070 target $0.080 for almost five years $0.060 $0.040 $0.020 $0.000 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4

  6. Slide 6: Investment track record of mostly singles and doubles

    Investment track record of mostly singles and doubles – Emphasis on consistency and reduced risk Unlevered Returns have been consistent over the years (32 Realized Transactions)1 Realized Gross IRR 45% Realized Gross IRR Realized Net IRR 40% 35% 28% (9) Realized Gross / Net IRR 30% > 15.0% 25% 20% 1

  7. Slide 7: The right structure / LTV helps generate attractive returns on debt

    The right structure / LTV helps generate attractive returns on debt irrespective of equity performance Life Sciences Debt Investments were less risky and are generally exposed to less volatility than an equity investment in the corresponding issuer ■ The chart below shows the gross and net multiple

  8. Slide 8: New investments have allowed BPCR to broaden its diversification

    New investments have allowed BPCR to broaden its diversification and deploy cash from capital raises and loan repayments Evolution of BPCR Portfolio since IPO1 (US$m) $1,800 Cash Seed Assets $1,600 Other Realized (repaid) Investments Outstanding Investments $1,400 $1,200 $1,000 $800 $600 $400 $200 $

  9. Slide 9: BPCR currently has ~$1.3bn invested across transactions

    BPCR currently has ~$1.3bn invested across 13 transactions ($ millions) BPCR Original Projected IRR Total Outstanding Remaining Investment Share (%) Share ($) Loan Amt. to Maturity1 Invested Balance Tranches Outstanding Balances + Cash Bristol Myers $97.6 High single % 100% $97.6 $97.6 $89.7 (As of

  10. Slide 10: BPCR's portfolio is primarily senior secured loans to listed companies

    BPCR’s portfolio is primarily composed of senior secured loans to listed companies Investment: Investment Investment Date: November 1, 2017 September 12, 2019 November 25, 2019 March 22, 2022 March 29, 2021 December 14, 2021 January 5, 2022 Investment Structure: Royalty Stream Secured Loan Secured L

  11. Slide 11: The Gross Yield of the Portfolio has Benefited from Higher Reference Rates

    The Gross Yield1 of the Portfolio has Benefited from Higher Reference Rates and an Increase in Floating Rate Investments Floating vs. Fixed2 10% 27% 27% Fixed 90% 73% 73% Floating YE 2022 Q1 23 PF 2Q 23 3Q23 estimated Gross Yield1 Gross Yield1: 13.1% 13.0% 12.0% 11.0% 12.1% 11.7% 10.0% 10.8% 9.0% 9.

  12. Slide 12: Current Valuation of BPCR Portfolio vs. Theoretical Value Using Bond Market Rates

    Current Valuation of BPCR Portfolio1 vs. Theoretical Value Using Bond Market Rates2 ■ The majority of BPCR’s investments are private loans that do not have an observable market value and are classified as “Level 3 Investments”. The fair values of the unlisted investments are determined principally b

  13. Slide 13: $275m senior secured corporate loan

    $275m senior secured corporate loan „ Reata: A global biopharmaceutical company that identifies, develops, and commercializes novel mechanisms of action for the treatment of severe life-threatening diseases that have few or no approved therapies „ Market Cap: $6.4bn as of August 25, 2023 „ Cash: $33

  14. Slide 14: $450m senior secured corporate loan

    $450m senior secured corporate loan „ BioCryst: A global biopharmaceutical company that discovers and commercializes novel, oral, small-molecule medicines „ Market Cap: $1.4bn as of August 25, 2023 „ Cash: $416m as of June 30, 2023 „ LTM Sales: $283m as of June 30, 2023 „ Main Product: Orladeyo™ (be

  15. Slide 15: $125m senior secured corporate loan

    $125m senior secured corporate loan „ ImmunoGen: A commercial-stage biotechnology company focused on developing and commercializing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients „ Market Cap: $4.0bn as of August 25, 2023 „ Cash: $572m as of June 30, 2

  16. Slide 16: $100m senior secured corporate loan

    $100m senior secured corporate loan „ Immunocore: A commercial stage biopharmaceutical company focused on developing a novel class of TCR bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune diseases „ Market Cap: $2.8bn as of August 25,

  17. Slide 17: $350m senior secured corporate loan

    $350m senior secured corporate loan „ Insmed: Global biopharmaceutical company focused treating patients with serious and rare diseases „ Market Cap: $3.1bn as of August 25, 2023 „ Cash: $918m as of June 30, 2023 „ LTM Sales: $257m as of June 30, 2023 „ Main Product: Arikayce® (amikacin liposome inh

  18. Slide 18: $650m senior secured loan to finance Collegium's acquisition of BDSI

    $650m senior secured loan to finance Collegium’s acquisition of BDSI „ Collegium Pharmaceutical: biopharmaceutical company focused on developing and commercializing new medicines for responsible pain management. „ Market Cap: $829m as of August 25, 2023 „ Cash: $326m as of June 30, 2023 „ LTM 2Q23 S

  19. Slide 19: $100m senior secured corporate loan

    $100m senior secured corporate loan „ UroGen: Biopharmaceutical company focused on developing products to treat specialty cancers and urologic diseases. UroGen’s products are being developed as chemoablation agents designed to remove tumors by non- surgical means. UroGen is focused on treating non-m

  20. Slide 20: $300m senior secured corporate loan

    $300m senior secured corporate loan1 „ Coherus BioSciences: Biopharmaceutical company building a leading immuno-oncology franchise funded with cash generated by its commercial biosimilars business „ Market Cap: $444m as of August 25, 2023 „ Cash: $145m as of June 30, 2023 „ LTM Sales: $210m as of Ju

  21. Slide 21: $125m senior secured corporate loan

    $125m senior secured corporate loan „ Evolus: Biopharmaceutical company with a customer-centric approach focused on delivering breakthrough performance beauty products „ Market Cap: $516m as of August 25, 2023 „ Cash: $42m as of June 30, 2023 „ LTM Sales: $160m as of June 30, 2023 „ Main Product: Je

  22. Slide 22: $331m senior secured corporate loan

    $331m senior secured corporate loan „ LumiraDx: A next-generation point-of-care (POC) diagnostic company addressing the current limitations of legacy POC systems by bringing lab- comparable performance in minutes on a single instrument for a broad menu of tests with a low cost of ownership. „ Market

  23. Slide 23: $100m senior secured corporate loan

    $100m senior secured corporate loan „ Akebia Therapeutics is a biopharmaceutical company focused on the development and commercialization of therapeutic for patients with kidney disease. „ Market Cap: $214m as of August 25, 2023 „ Cash: $54m as of June 30, 2023 „ LTM Sales: $176m as of June 30, 2023

  24. Slide 24: $130m senior secured corporate loan

    $130m senior secured corporate loan „ Optinose: Specialty pharmaceutical company focused on products for patients treated by ear, nose, and throat (ENT) and allergy specialists. „ Market Cap: $143m as of August 25, 2023 „ Cash: $71m as of June 30, 2023 „ LTM Sales: $75m as of June 30, 2023 „ Main pr

  25. Slide 25: Life Sciences is a $1 Trillion+ Vital Industry with Sales that are Uncorrelated

    Life Sciences is a $1 Trillion+ Vital Industry with Sales that are Uncorrelated and Unaffected by Economic Cycles Global Historical Pharmaceutical Sales ($ in trillions) COVID-19 $1.5 Global Financial $1.5 Crisis R $1.3 % CAG $1.3 6.6 $1.1 $1.2 $1.1 $1.1 $1.1 $1.0 $1.0 $1.0 $0.9 $0.8 $0.8 $0.7 $0.6

  26. Slide 26: Life Sciences is a $1 Trillion+ Vital Industry (cont'd)

    Life Sciences is a $1 Trillion + Vital Industry with Sales that are Uncorrelated and Unaffected by Economic Cycles (cont’d) Annual Changes in Sales of Oncology Drugs vs Major Indices 100% $140 Oncology Sales $Bn 80% $120 NASDAQ (% change) 60% $100 40% $80 20% $60 0% $40 (20%) (40%) $20 (60%) $0 1990

  27. Slide 27: Small and midsize companies are involved in a majority of newly approved drugs

    Small and midsize companies (target borrowers) are involved in a majority of newly approved drugs Drug Approvals by Size of Drug Originator 2009 - 2020 Source: Bloomberg, Pharmakon 26

  28. Slide 28: Choppy biotech equity markets created an attractive environment for debt investments

    Choppy biotech equity markets historically created an attractive environment for debt investments in biotech XBI Biotech Index Price Performance1 60% 44% 35% 40% 25% 22% 16% 20% 0% (20%) (4%) (23%) (40%) (38%) (60%) 2015 2016 2017 2018 2019 2020 2021 2022 Convert Count and Proceeds $30 80 Total Amou

  29. Slide 29: All four previous BioPharma Credit private funds have returned all capital

    All four previous BioPharma Credit private funds have returned all capital to investors Pharmakon Advisors, LP Private Fund Historical Investment Performance (Private Funds) I II III IV Launch Date June 2009 March 2011 February 2013 December 2015 „ Founded in 2009; manager of the BioPharma Credit fu

  30. Slide 30: Gross and Net Returns of Past Realized Investments

    Gross and Net Returns of Past Realized Investments1 Investment Date Investment Name Fund Investment Amount Gross IRR 1 Net IRR1 Gross MOIC 1 Net MOIC1 Jun 2009 LEXIVA Private Fund I $25,901,597 22% 18% 1.37x 1.30x Sep 2009 Cymbalta Private Fund I $132,000,000 15% 11% 1.20x 1.16x Oct 2009 PDL Private

BioPharma Credit — Debt Investor Presentation (September 2023) on 6ix